Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J.

Solove Research Institute (OSUCCC—James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers. The findings are published in Blood Cancer Discovery.